How should functionally equivalent drugs be reimbursed? A retrospective analysis of reimbursement for Epoetin-[alpha] and Darbepoetin-[alpha] in 2001-2003 and the cost implications for CMS

Kanavos, P.ORCID logo & Saka, Ö. R. (2005). How should functionally equivalent drugs be reimbursed? A retrospective analysis of reimbursement for Epoetin-[alpha] and Darbepoetin-[alpha] in 2001-2003 and the cost implications for CMS. Disease Management and Health Outcomes, 13(6), 359-370.
Copy
Item Type Article
Copyright holders © 2005 Adis International Ltd
Departments LSE > Academic Departments > Social Policy
LSE > Academic Departments > European Institute
LSE > Research Centres > LSE Health
Date Deposited 04 Sep 2008
URI https://researchonline.lse.ac.uk/id/eprint/15045

Explore Further

Full text not available from this repository.

Export as

EndNote BibTeX Reference Manager Refer Atom Dublin Core JSON Multiline CSV
Export

Downloads
View more statistics